AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, A TOP RANKED LAW FIRM, Encourages Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline

A securities class action has been filed against Aardvark Therapeutics, alleging that disclosures around ARD-101 understated safety concerns and overstated the drug candidate’s clinical, regulatory, and commercial prospects; these are allegations, and no class has been certified. Investors who purchased securities in the February 13, 2025 IPO or during the February 13, 2025–May 14, 2026 class period have an October 13, 2026 deadline to seek lead-plaintiff status.

Analysis

The near-term signal is procedural, not a new finding about ARD-101: a lead-plaintiff deadline can attract attention and increase headline volatility, but does not establish that the safety allegations are true or that a class will be certified. The more consequential issue is whether the alleged safety gap is supported by clinical, regulatory, or company disclosures. If verified, the impact could extend beyond litigation costs: lower odds of advancing ARD-101 would reduce the value of the program and potentially worsen AARD’s access to capital, while creating an opening for competing approaches. Those effects are conditional; the notice supplies no new trial data or independent corroboration.

Over the next several days, expect possible volatility around the October 13 deadline, with direction dependent on the docket and company response—not the deadline itself. Over 1–3 months, monitor court filings and any clinical or regulatory update that clarifies the safety record. Over 6–18 months, the key structural risk is whether the program remains viable and fundable. The contrarian point: legal-notice volume can make litigation appear like a fresh fundamental catalyst when the complaint was already filed; conversely, investors may underweight the financing consequences if safety concerns prove substantive. No reliable peer trade is identifiable from the supplied facts.

Key Decisions for Investors

• Do not initiate a standalone short solely on this solicitation. The allegations are unproven, and the notice adds no new clinical evidence; borrow availability, liquidity, and current valuation are also unknown.
• For existing AARD exposure, keep position size disciplined through October 13 and review the court docket, company disclosures, and the underlying safety data before treating the case as a change in program value.
• Consider a defined-risk bearish position only if independently verified safety evidence or a company/regulatory update weakens ARD-101’s prospects, and only after checking options liquidity and pricing. Reassess if subsequent data or regulators support the program’s safety profile.
• Falsifiers and alerts: a court filing that materially narrows the allegations, credible clinical/regulatory evidence supporting safety, or continued program advancement would weaken the downside thesis; a trial hold, adverse safety update, or company guidance change would strengthen it. Verify AARD’s cash runway and funding needs before modeling dilution risk.